Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

The primary endpoint (time to first on study relapse) showed a clear trend in favor of continued NTZ treatment, however, statistical significance was not reached probably due to the small sample size.

also in 19,460 other papers

While time to first on-study relapse was not significantly different between groups (p=0.125), many secondary clinical and radiological endpoints (number of relapses, proportion of relapse free patients, number of new T2 lesions) showed a trend, or were significant (new T2 lesions at month 6) in favoring NTZ.

also in 53,322 other papers